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Abstract
Surgical resection or liver transplantation (LTx) are the only available treatments that offer a potential for long-term survival
or cure in cases of hilar cholangiocarcinoma. Hilar resection in combination with partial hepatectomy and caudate lobectomy
is regarded as the current treatment of choice. Overall 5-year survival rates range from 9% to 28%, and reach as high as
24–43% in R0 resections. Five-year survival rates in the very limited experience with LTx in hilar cholangiocarcinoma are not
dramatically worse than those after resection. However, hilar cholangiocarcinoma is not at present an accepted indication for
LTx given both the good results of LTx for benign diseases and the dramatic organ shortage. When compared with the
prognosis of other gastrointestinal tumours, these survival rates are encouraging in the setting of an otherwise
unresectable malignancy. As such, and considering the fact that it may represent the only possibility for cure, the general
exclusion of patients with cholangiocarcinomas as candidates for LTx does not seem to be justified. Furthermore, recent
advances in multimodal tumour therapy seem to be most promising in combination with LTx. Prospective studies are required
to elucidate the influence of better patient selection and the role of multimodal treatments on the outcome of LTx in hilar
cholangiocarcinoma. If the encouraging data achieved with neoadjuvant therapy prior to LTx are confirmed by further
studies, we foresee that renewed interest in LTx for hilar cholangiocarcinoma could arise.
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Introduction
Surgical resection is regarded as the current treatment
of choice for hilar cholangiocarcinoma. Overall 5-year
survival rates range from 9% to 28%, and reach as high
as 24–43% in R0 resections [1–11]. Although recent
results of the very limited experience with liver
transplantation (LTx) in hilar cholangiocarcinoma are
not dramatically worse than those after resection, hilar
cholangiocarcinoma is currently not an accepted
indication for LTx because of the satisfactory outcome
of LTx for benign diseases and the dramatic organ
shortage (Table I) [1,12–25].
In the early periods of LTx, irresectable hepatobiliary
malignancies including hilar cholangiocarcinoma were
favoured indications, as such patients were usually in
good physical condition and operative technical
problems were diminished by the absence of severe
portal hypertension and end-stage liver disease.
However, the initial good clinical outcome was followed
by a high tumour recurrence rate, and most patients
died within 1 or 2 years after transplantation [20,26–28].
These results led many centres to abandon LTx for
cholangiocarcinoma, mostly to avoid the waste of
otherwise needed donor organs for benign diseases.
As such, only few data were generated on the outcome of
LTx for hilar cholangiocarcinoma, and the very few
series available were hampered by small numbers of
patients, lack of clear differentiation between hilar and
intrahepatic cholangiocellular carcinoma, and poor
stratification of results with regard to surgical radicality
and tumour staging.
Our report provides an overview of the experience
with LTx for hilar cholangiocarcinoma, and attempts
to outline whether there is still a place for liver grafting
in the management of this pathology.
LTx plus Whipple
The initial experience with LTx for hilar cholangio-
carcinoma was impaired by low survival rates due to
frequent tumour relapse, usually loco-regional rather
than distant. In particular, a considerable incidence of
tumour recurrence was observed in the region of the
head of the pancreas, pointing to an inadequate
resection margin at the common bile duct and upper
part of the pancreas as a potential contributing factor.
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In an attempt to overcome this problem, Jonas and
Neuhaus proposed to extend the bile duct resection by
combining LTx with partial pancreatoduodenectomy
[17]. This approach eradicated the entire biliary tree
and complied with the basic rule of oncologic surgery
of achieving wide safety margins while carrying no
dissection in tumour-bearing areas. A similar resection
approach was also described by Anthuber et al. [14]
and by Cherqui et al. [13]. The overall 60-day-
mortality in these series was 15% (3/20). However,
although with this approach the rates of potentially
curative resections rose up to 93%, long-term outcome
showed no significant improvement. The 4-year
survival rate in 14 patients described by Neuhaus was
30%, and tumour recurrence still accounted for most
deaths [3,13,14,17].
Cluster-LTx
The Starzl group introduced an even more aggressive
approach by combining LTx with resection of all visceral
organs derived from the foregut (liver, stomach, spleen,
pancreatoduodenal complex) and part of the colon. In
an analysis of 12 patients undergoing this so-called
upper abdominal exenteration with subsequent cluster-
transplantation (liver, pancreas, duodenum and variable
amounts of jejunum) or solely liver transplantation,
Alessiani et al. observed long-term survivals (52, 54 and
59 months) in three patients, all of them with nodal
negative hilar cholangiocarcinomas. However, this
procedure carried a significant morbidity, and a
3-month mortality of 17% [12]. Since postoperative
deaths were associated with complications of the
pancreatic graft, transplantation of the liver alone was
advocated despite the onset of surgically induced
diabetes. Subsequent modifications to this approach,
such as the pylorus-preserving cluster operation
introduced by Launois and Jamieson, were aimed at
improving nutritional results, but long-term results and
large-series data are not yet available [29].
Although there is no doubt that some of
the drawbacks and technical failures of LTx in
combination with Whipple operations or multivisceral
resections might have been overcome with increasing
experience, such aggressive procedures never gained
wide acceptance. The unconvincing long-term results
suggest that there is a limit to the contribution made by
radical resections alone.
Consequently, the importance of better patient
selection and the enrolment of LTx as part of a
multimodal treatment concept has gained wider
acceptance. This can be explained on the one
hand by the experience with LTx for hepatocellular
carcinoma (HCC) in the setting of cirrhosis, where
patients who could have undergone hepatic resection
had better outcomes after LTx. On the other hand,
significant contributions have been made by ongoing
developments in oncologic surgery, where tumour
resection is combined with neoadjuvant treatments.
Prognostic factors
In recent years, some more detailed analyses have been
published, allowing for a better assessment of the role
of LTx in the treatment of hilar cholangiocarcinoma.
Although the number of transplants continues to be
small, most studies show a negative prognostic
correlation between survival and both lymph node
involvement and tumour depth. In particular, tumours
confined to the ductal wall (T1) or infiltrating the
perifibromuscular connective tissue but with no
involvement of vascular or adjacent structures (T2)
are associated with a significantly better survival than
more advanced tumours. Pichlmayr et al. [1] achieved
Table I. Review of literature regarding liver transplantation (LTx) in hilar cholangiocarcinoma
Ref. no. Author Year LTx (n) Operative extension (n) Neo-/adjuvant treatment (n) Survival
12 Alessiani* 1995 12 (12) Cluster-Tx – 25% 4 years
13 Cherqui 1995 2 (2) Whipple (2) RTx 23 months (med.)
14 Anthuber 1996 10 (4) Whipple – 25 months (med.)
1 Pichlmayr 1996 25 – – 15.5 months (med.) 21.4% 3 years
15 Beckurts 1997 5 – (5) IORT 12 months (med.)
16 Iwatsuki* 1998 38 (11) Cluster-Tx (18) RTx+5-FU 12.7 cum 26% 5 years
17 Jonas 1998 14 Whipple – 30% 4 years
18 De Vreede# 2000 11 – (11) RTx+5-FU 44 months (med.)
19 Figueras** 2000 8 – (8) RTx+5-FU 88% 3 years
20 Shimoda 2001 5 – – 31% 3 years
21 Sudan 2002 11 – (11) BBT+5-FU 17 months (med.)
22 Robles** 2004 36 – – 55 months (cum.) 53% 3 years
23 Heimbach# 2004 28 – RTx+5-FU+ 82% 5 years
BBT+5-FU/Gemcitabine
24 Rea# 2005 38 – RTx+5-FU+ 87% 5 years
BBT+5-FU/Gemcitabine
25 Zheng 2005 5 – – 30 months (med.) 80% 3 years
RTx, radiation therapy; IORT, intraoperative radiation therapy; BBT, biliary brachytherapy; 5-FU, 5-fluorouracil. *, ** and #: data may overlap.
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1-, 3- and 5-year survival rates of 89%, 56% and 44%,
respectively, after LTx (n=9) for hilar cholangio-
carcinoma classified as pT1N0 or pT2N0. These rates
compare with 37%, 0% and 0%, respectively, for more
advanced tumours. Similarly, Iwatsuki et al. [16]
reported 1-, 3- and 5-year survival rates of 68%, 50%
and 50%, respectively, in 28 transplants with nega-
tive surgical margins and negative lymph nodes.
Comparable results were reported by Robles et al.
[22] with a 5-year survival rate of 36% in 36 patients
after LTx for hilar cholangiocarcinoma.
From an oncologic point of view, 5-year survival
rates of 30–50% in highly selected patients with
otherwise unresectable tumours are extremely good.
Although these data are too few to draw further
conclusions and need to be confirmed by larger series,
these encouraging results suggest that a systematic
denial of LTx for hilar cholangiocarcinoma does not
seem to be justified. Furthermore, since these survival
rates after LTx are observed in cases of otherwise
unresectable tumours, one may speculate that these
results may improve even further if smaller and still
resectable tumours were considered. If so, there would
be no reason to exclude these patients from LTx. In
principle, these patients would also be candidates for
cadaveric LTx, something that by current standards is
not considered appropriate given the good results of
LTx for benign disease. However, in a manner similar
to the recent experience with LTx in HCC, marginal
donors not routinely accepted for transplantation of
other types of liver disease could be used for patients
with hilar cholangiocarcinomas.
The reports by Iwatsuki, Pichlmayr and Robles
et al. [1,16,22] are significant not only because they
underline the importance of patient selection, but also
because they illustrate the lack of diagnostic accuracy
in tumour staging of hilar cholangiocarcinomas.
While the T-category of hilar cholangiocarcinoma is
difficult to assess preoperatively—something that limits
its use as a selection criterion—the negative prognostic
impact of tumour-positive lymph nodes could be
addressed prior to transplantation in two possible
ways. Candidates could undergo either an explorative
laparotomy with complete lymphadenectomy of
the hepatic hilum prior to LTx, or a systematic
and complete lymphadenectomy with immediate
assessment by frozen section at the time of LTx.
Although the first approach carries the disadvantage of
an additional surgery prior to LTx, it allows for a more
accurate staging, prevents logistic problems associated
with the performance of multiple frozen sections at the
time of transplantation, and is not associated with a
potentially longer allograft preservation time. The
second approach has the disadvantage that in cases of
tumour-positive lymph nodes, the switch to a back-up
patient could result in further prolongation of the cold
ischaemic time of the liver. Nevertheless, since patients
with negative findings at staging laparotomy may still
develop peritoneal carcinomatosis and intrahepatic
tumour spread while on the waiting list, back-up
patients are mandatory for both approaches.
Multimodal treatment concepts
In 1998, Iwatsuki et al. reported on a larger number
of patients (n=22) undergoing LTx in combination
with various protocols of adjuvant external radiation
therapy with or without 5-fluorouracil (5-FU) sensiti-
zation prior to and after the operation. Their results
showed a significant survival benefit for patients
receiving adjuvant therapy (mean survival of 16.7
months) when compared with those undergoing LTx
alone (mean survival of 12.3 months). However, the
difference became insignificant when patients who died
within 3 months after operation were excluded from
the analysis [16].
In recent years, surgical treatment of hilar cholangio-
carcinoma has been further enriched by the
introduction of intraoperative radiotherapy (IORT)
[30]. This approach aims to address one of the main
problems in resection surgery of Klatskin tumours: the
development of loco-regional recurrence caused by
both perineural tumour invasion and very small
safety margins at the hepatic ducts. Not long ago,
Sotiropoulos from our group reported on a 10-year
survivor pretreated with IORT at staging laparotomy
6 weeks prior to LTx for an unresectable hilar
cholangiocarcinoma [31]. Although the exact
contribution of IORT to long-term survival in this
single case remains undetermined, the potential
of IORT in local tumour control prior to or at the time
of LTx seems worthy of consideration.
Recently, very promising data from the Mayo
Clinic have been reported by Heimbach et al. [23].
In this ongoing study, a total of 56 patients underwent
neoadjuvant therapy including external beam
irradiation with a radiosensitizing bolus of 5-FU
chemotherapy, followed by a transcatheter Iridium-
192 brachytherapy boost and either intravenous 5-FU
or oral capecitabine prior to LTx. Four patients died
during the therapy, and another four had evidence
of tumour progression prior to completion of the
neoadjuvant treatment. Fourteen of the remaining 48
patients were further excluded due to the presence of
tumour-positive lymph nodes at the time of routine
staging laparotomy. Twenty-eight patients underwent
LTx with an operative mortality rate of 11% and a
5-year survival rate of 82%. In a subsequent follow-up
expanded report of the same group by Rea et al. in 2005
[24], a total of 38 patients had already undergone LTx
after neoadjuvant therapy, with actual 1-, 3- and 5-year
survival rates of 91%, 87% and 87%, respectively.
In an approach similar to that of the Mayo
Clinic, Sudan et al. [27] introduced a neoadjuvant
protocol that included 6.000 cgy biliary brachytherapy
delivered through percutaneous transhepatic catheters
and intravenous 5-FU (300 mg/m
2/day) until
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transplantation. The drop-out rate in this study was
35% (6/17). Eleven patients were transplanted at a
median of 3.4 months after diagnosis, with three of
them dying in the perioperative period. Only two of
the remaining eight patients experienced tumour
recurrence, with five being alive without evidence
of disease at a median follow-up of 7.5 years (range
2.8–14.5 years).
In Rea’s series, 29 of the 38 hilar cholangio-
carcinomas (76%) did not originate in a normal liver
but were associated with primary sclerosing cholangitis
(PSC) [24]. Similarly, in Sudan’s series, 6/11 patients
with hilar cholangiocarcinoma also had a diagnosis of
PSC. This is of relevance, as the presence of PSC might
have influenced and at least partially contributed to the
excellent results of these studies. It is most likely that in
patients routinely screened because of known PSC,
hilar cholangiocarcinoma may be diagnosed at earlier
stages than in patients without concomitant disease. In
addition, concomitant liver disease may also preclude
major hepatectomies despite small and potentially
resectable tumours. Therefore, the results of these two
studies are not completely comparable with data from
most other studies that do not include hilar cholangio-
carcinoma in the presence of PSC.
So far, since there is no prospective randomized
study with a control group—which admittedly would
be difficult to justify in view of the excellent results—it
is hard to decide whether the extremely good results
after LTx in these studies could be attributed to the
very strong selection criteria rather than to the
neoadjuvant therapy. Therefore, as long as the effects
of the neoadjuvant therapy are not clearly determined,
its side effects should be weighed very carefully.
Regardless of such obstacles, these two approaches
currently provide the most promising and encouraging
treatment modalities for hilar cholangiocarcinoma, and
merit both careful attention and further evaluation.
LDLTx
The increasing experience with living donor LTx
(LDLTx) has led to an ongoing discussion on extended
indications for LTx in hepatobiliary malignancies, in
particular for HCCs not satisfying the Milan or UCSF
criteria [32,33]. Such an approach offers a chance for
prolonged survival or even cure for patients who would
otherwise not qualify for LTx. The controversy
surrounding this topic is whether it is ethically justified
to subject a healthy person to the risks of a living donor
hepatectomy when the prognosis of the recipient is
supposed to be limited. Oncologically, in contrast to
transplantation with deceased donor livers, LDLTx
offers the only possibility for a scheduled transplan-
tation after prior neoadjuvant tumour therapy, thus
optimizing its effects. This becomes especially relevant
when considering the Mayo Clinic and Sudan series
with neoadjuvant therapy. If these data are confirmed
by further studies, the indications for LTx in hilar
cholangiocarcinoma as well as a general acceptance of
LDLTx will become prominent topics of discussion.
Conclusion
Five-year survival rates in the very limited experience
with LTx in hilar cholangiocarcinoma are not
dramatically worse than those after hilar resection in
combination with partial hepatectomy. However, it
is currently not accepted practice to allocate the
scarce donor organs to patients suffering from hilar
cholangiocarcinoma given the superior results
obtained in cases of LTx for benign diseases. From
an oncologic point of view, a 5-year survival rate of
430% for a highly aggressive gastrointestinal tumour
is a more than acceptable result. As such, and
considering the fact that it may represent the only
possibility for cure, the general exclusion of patients
with cholangiocarcinomas as candidates for LTx does
not seem to be justified. With regard to the present
dramatic organ shortage, the use of marginal donor
livers otherwise not accepted for patients with
end-stage liver disease could provide a much-needed
alternative [34,35].
While aggressive surgical approaches such as LTx in
combination with Whipple operations or upper
abdominal exenterations have failed to improve the
results of LTx in cases of hilar cholangiocarcinoma,
recent advances in multimodal tumour therapy seem
to be most promising in combination with LTx. This
is particularly true in selected patients (i.e. those
with lymph node-negative T1 or T2 tumours) or
when concomitant liver cirrhosis precludes a partial
hepatectomy in otherwise resectable cholangio-
carcinomas. Since most current series of LTx for hilar
cholangiocarcinoma include only cases of unresectable
tumours, it would not be unreasonable to speculate
that survival rates would improve even more if, in a
manner similar to the experience with LTx in HCC,
small and still resectable tumours were considered.
Prospective studies are required to elucidate the
influence of better patient selection and the role of
multimodal treatment on the outcome of LTx in hilar
cholangiocarcinoma. If the encouraging data achieved
with neoadjuvant therapy prior to LTx are confirmed,
then not only the general reluctance to proceed with
LTx in cases of hilar cholangiocarcinoma will be
questioned, but also a discussion about the application
of LDLTx could arise.
In conclusion, reviewing the cumulated experience
with LTx for hilar cholangiocarcinoma it seems
worthwhile to revisit its place of indication anew.
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